Clinical Trials
Boehringer Ingelheim’s lead hepatitis C compound moves into phase III – the first within the BI HCV portfolio
Boehringer Ingelheim announced the study outline for the pivotal Phase III clinical trials designed to evaluate BI 201335, its investigational once-daily oral protease inhibitor, in both treatment-naïve and -experienced patients with chronic genotype-1 hepatitis C virus (HCV), the most...
Clinical Trials
Addex Initiates Phase IIa Clinical Trial of Dipraglurant-IR in Parkinson’s Disease Levodopa-Induced Dyskinesia (PD-LID)
Allosteric modulation company Addex Pharmaceuticals (SIX:ADXN) announced today the initiation of a Phase IIa clinical trial to evaluate dipraglurant in patients with Parkinson’s disease levodopa-induced dyskinesia (PD-LID), a debilitating movement disorder caused by long-term treatment with levodopa, the...
Clinical Trials
Adocia reports positive phase I clinical results on HinsBet(R), a fast-acting human insulin
Adocia, a privately-held biotechnology company specialized in regenerative medicine and in the treatment of chronic diseases, announced today positive results from its phase I clinical study evaluating the safety and clinical utility of HinsBet(R), its fast-acting human insulin product...
Clinical Trials
Infinity Initiates Phase 2 Trial of IPI-926 in Patients With Chondrosarcoma
Infinity Pharmaceuticals, Inc. announced the initiation of a randomized, double-blind Phase 2 clinical trial to evaluate the safety and efficacy of IPI-926 compared to placebo in patients with metastatic or locally advanced, inoperable chondrosarcoma. The trial is expected to...
Clinical Trials
NovaBay Pharmaceuticals Initiates Phase 2 Clinical Trial for the Treatment of Urinary Catheter
NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing its first-in-class, anti-infective Aganocide compounds for the local non-systemic treatment and prevention of antibiotic-resistant infections, today provided an update on its Phase 2 clinical trial for the use of its...
Clinical Trials
GlaxoSmithKline and Human Genome Sciences announce publication of BLISS-52 phase lll study results
GlaxoSmithKline (GSK) and Human Genome Sciences, Inc. announced publication of the BLISS-52 study of Benlysta® (belimumab) in autoantibody-positive patients with active systemic lupus erythematosus (SLE) in The Lancet. The BLISS-52 study, one of two pivotal...
Clinical Trials
Plexxikon Initiates Phase 1 Clinical Trial for Oral Rheumatoid Arthritis Agent PLX5622
Plexxikon Inc. announced that dosing began in the first of two Phase 1 clinical trials with PLX5622, a novel, oral and highly selective Fms inhibitor, targeted for the treatment of rheumatoid arthritis (RA). PLX5622 has been shown in preclinical...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.